Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double‐Blind, Randomized, Placebo‐Controlled Trial

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Their role in patients without heart failure, particularly in patients with coronary artery disease (CAD) and preserved EF, is still a matter of debate. H...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cardiol
Autori principali: Sudano, Isabella, Naegele, Matthias, Roas, Susanne, Périat, Daniel, Frank, Michelle, Kouroedov, Alexey, Noll, Georg, Lüscher, Thomas F., Enseleit, Frank, Ruschitzka, Frank, Flammer, Andreas J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wiley Periodicals, Inc. 2016
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490773/
https://ncbi.nlm.nih.gov/pubmed/26991772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22528
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi